Biotechnology is behind lifesaving vaccines, novel therapies for rare cancers, and breakthroughs for everything from heart disease to Alzheimer’s. Once a niche within the biopharmaceutical sector, biologics-drugs derived from living cells-now account for a growing share of new therapies and industry revenue.
In the latest episode of Exceptional Leaders / Exceptional Ideas, Matthew Harrison, Equity Analyst covering Biotechnology, sits down with Bob Bradway, Chairman and CEO of Amgen, to talk about how one of the world’s leading biotechnology companies thinks about investing in innovation, hiring top talent, and using technology to improve drug development.
Learn more: mgstn.ly/3FzQWM5